Eli Lilly announced an exclusive global licensing and research collaboration with Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. The collaboration includes up to four innovative preclinical immunometabolism targeted therapeutics, including Sitryx’s two lead projects.
The 5-year research collaboration will support the development of the therapeutics, with Sitryx responsible for drug discovery, and Lilly will fund and manage the clinical development and commercial phase of the collaboration.
Under the terms of the agreement, Sitryx will receive an upfront payment of $50 million and Lilly will make a $10 million equity investment in Sitryx. Sitryx will be eligible to receive potential development milestones up to $820 million, as well as commercialization milestones and royalty payments on potential sales in the mid to high-single digit range. In return, Sitryx will grant Lilly an exclusive, worldwide license to develop and commercialize up to four novel immunometabolism targeted therapeutics, including Sitryx’s two lead projects.
Sitryx’ scientific focus is based on existing data in the field of immunometabolism, which supports the key hypothesis that it is possible to manipulate intracellular metabolic pathways in specific cells to alter their activity and bring about a disease-modifying effect. Given the emerging nature of the field, Sitryx scientists are currently exploring multiple metabolic pathways within immune cells to identify potential ‘druggable’ targets for the development of groundbreaking new therapies for treating cancer and inflammation.